[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
April 1986

Immune Response of Infants and Children to Low-Passage Bovine Rotavirus (Strain WC3)

Author Affiliations

From the Wistar Institute of Anatomy and Biology, Philadelphia (Drs Clark, Furukawa, and Plotkin and Ms Perrella); Children's Hospital of Philadelphia (Drs Clark, Bell, Offit, and Plotkin); and Kanazawa Medical University, Ishigawa-Ken, Japan (Dr Furukawa). Dr Offit is now with the Division of Gastroenterology, Veterans Administration Medical Center, Palo Alto, Calif.

Am J Dis Child. 1986;140(4):350-356. doi:10.1001/archpedi.1986.02140180084030

• A bovine rotavirus (strain WC3) was isolated from a calf in Pennsylvania and adapted to growth in continuous Cercopithecus cell line CV1. A pool for human vaccine trials was produced at the 12th cell culture passage level. After preliminary testing in adults and older children, a dose of 3×107 plaque-forming units was given by mouth to 52 infants and children aged 5 months to 6 years. No clinical sequelae were detected, and shedding in feces was detected in only 30% of tested infants. A serum-neutralizing antibody response was induced in 95% of 21 infants aged 5 to 11 months; response rates were slightly reduced in older infants. The antibody response was primarily directed toward bovine rotavirus, but a response to human serotype 3 rotavirus was also observed in approximately 50% of vaccinees. After vaccination with WC3, infants with preexisting antibody to rotaviruses of human serotype 1 or 3 frequently exhibited a booster response to those serotypes. WC3 is a candidate rotaviral vaccine deserving larger trials in children.

(AJDC 1986;140:350-356)